Pfizer: third dose being studied against Covid variants

(CercleFinance.com) - The US pharmaceuticals giant Pfizer said on Thursday that, alongside its German partner BioNTech, it will conduct a clinical study to assess the effectiveness of a third dose of their Covid vaccine against new mutations in the virus.


The groups said that the Phase 1 trial - to be conducted in the US - will consist of a booster jab of the vaccine six to 12 months after the initial injection.

In addition, Pfizer and BioNTech report that they are in talks with the US and European health authorities to initiate a clinical study to evaluate the principle of a modified mRNA sequence for variants of the virus.

The project - which is initially based on the specificities of the South African variant - would enable both laboratories to rapidly adapt their vaccine to the new circulating Covid strains, they explained.


Copyright (c) 2021 CercleFinance.com. All rights reserved.